Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

44.37
+0.02000.05%
Post-market: 43.73-0.6392-1.44%19:30 EDT
Volume:846.60K
Turnover:37.69M
Market Cap:9.16B
PE:-15.75
High:45.12
Open:44.85
Low:44.08
Close:44.35
52wk High:45.42
52wk Low:14.47
Shares:206.40M
Float Shares:89.57M
Volume Ratio:0.74
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8178
EPS(LYR):-2.7716
ROE:-80.10%
ROA:-46.73%
PB:12.45
PE(LYR):-16.01

Loading ...

Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype

Simply Wall St.
·
Aug 15

Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Immunovant Fiscal Q1 2027 Results: IMVT-1402 Spending Widens Net Loss

TradingKey
·
Aug 06

Immunovant reports Q2 EPS (75c), consensus (61c)

TIPRANKS
·
Aug 06

Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million

Reuters
·
Aug 06

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss

MT Newswires Live
·
Aug 06

Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate

Benzinga Earnings
·
Aug 06

Immunovant Q1 Net Income USD -153.224 Million Vs. IBES Estimate USD -130.2 Million

Reuters
·
Aug 06

Immunovant, - Cash and Cash Equivalents Total $797.80 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 06

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

TIPRANKS
·
Aug 04

Earning Preview: Immunovant, Inc. Q2 revenue is expected to be flat, and institutional views are predominantly bullish

Earnings Agent
·
Jul 31

Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares

Reuters
·
Jul 30

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700

Reuters
·
Jul 25

Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call

Reuters
·
Jul 24

Immunovant Announces Annual Shareholder Meeting

Reuters
·
Jul 23

Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million

Reuters
·
Jul 07

Chief Technology Officer Of Immunovant Sold 53% Of Their Shares

Simply Wall St.
·
Jul 02

Immunovant is Maintained at Buy by Citigroup

Dow Jones
·
Jul 01

Immunovant price target raised to $61 from $57 at Citi

TIPRANKS
·
Jun 30

Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015

Reuters
·
Jun 27